Novartis Ag (NVSEF) Net Income towards Common Stockholders Growth (5y) (2014 - 2026)

Novartis Ag (NVSEF) Net Income towards Common Stockholders Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Novartis Ag - - -

Historic Data

Download Data
DateValue
Mar 31, 2026 12.64%
Dec 31, 2025 6.49%
Sep 30, 2025 19.14%
Jun 30, 2025 20.35%
Mar 31, 2025 13.77%
Dec 31, 2024 23.22%
Sep 30, 2024 11.91%
Jun 30, 2024 -11.46%
Mar 31, 2024 11.21%
Dec 31, 2023 51.43%
Sep 30, 2023 3.96%
Jun 30, 2023 -19.77%
Mar 31, 2023 4.61%
Dec 31, 2022 -4.09%
Sep 30, 2022 -3.89%
Jun 30, 2022 -1.73%
Mar 31, 2022 7.39%
Dec 31, 2021 78.70%
Sep 30, 2021 8.71%
Jun 30, 2021 11.16%